The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The role of BTK inhibitors in the frontline treatment of MCL
Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, comments on the role of BTK inhibitors in the frontline setting for patients with mantle cell lymphoma (MCL), highlighting how these agents may impact the treatment landscape. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So BTK inhibitors have a tremendous impact in mantle cell and in the front-line space, there’s a couple of ways in which we’re starting to use them. I think first and foremost, for patients who are older or perhaps not great chemotherapy candidates, we have data to support either monotherapy use of covalent BTK inhibitors or in combination with rituximab. There are some larger trials going on to help us define the benefit of that approach, compared to chemoimmunotherapy in the MANGROVE trial...
So BTK inhibitors have a tremendous impact in mantle cell and in the front-line space, there’s a couple of ways in which we’re starting to use them. I think first and foremost, for patients who are older or perhaps not great chemotherapy candidates, we have data to support either monotherapy use of covalent BTK inhibitors or in combination with rituximab. There are some larger trials going on to help us define the benefit of that approach, compared to chemoimmunotherapy in the MANGROVE trial. And then we can also combine these BTK inhibitors with existing standards of care. So for example, this summer, the ECHO data showed us that combination of acalabrutinib with BR did lead to an improvement in progression-free survival and prolongs that time between start of first treatment and start of next treatment for patients. And then in the younger population, looking at perhaps consolidation with BTK inhibitors rather than, say, autologous transplant, which has been a mainstay. So really, I think across the spectrum, we’re starting to generate data that helps us define that BTK inhibitors are likely to play a big role.
Read more...
